Home > > > Report Detail

Real World Evidence Solutions Market by Component (Services, Disparate Data Sets, (Claims, Clinical, Pharmacy, Patient), Application (Oncology, Cardiovascular, Neurology, Immunology), End User (Pharma, Medtech, Payers, Providers) - Global Forecast to 2027

Publisher Name :
Date: 01-Nov-2022
No. of pages: 265
Inquire Before Buying

“The RWE solution market is projected to grow at a CAGR of 15.2% between 2022 and 2027.”

The global RWE Solutions market is projected to reach USD 2.9 Billion by 2027 from USD 1.5 Billion in 2022, at a CAGR of 15.2% during the forecast period. Rise in the geriatric population and the subsequent increase in the prevalence of chronic diseases and support from regulatory bodies for the use of RWE solutions is driving the growth of the RWE solutions market.  Given the large pool of geriatric individuals requiring health and long-term care services, the healthcare cost per person is expected to increase in many countries. Solutions such as EHR and population health management are being employed to reduce the burden on the overworked healthcare delivery systems in several countries. The significant amount of RWD that is being generated through digital health solutions is helping in better understanding clinical outcomes. As a result, the adoption of RWE solutions is increasing globally.

Pharmacy data is expected to witness the fastest growth during the forecast period

Based on component, the RWE solutions market is segmented into data sets and services. In 2021, services segment dominated the RWE solutions market owing to the availability of a large volume of healthcare data on the basis of which advanced analytics and consulting services can be offered. The data sets segment has been further segmented into disparate data sets and integrated data sets. The disparate data sets is further segmented into clinical settings data, claims data, pharmacy data, patient-powered data, and other data sets. The pharmacy data sets segment is expected to witness fastes growth rate during the forecast period owing to rising efforts to decrease medication no adherence and the increasing adoption of e-prescribing systems.

“Drug development and approvals dominates the RWE solutions market in 2021”

Based on the application, the RWE solutions market is broadly categorized into drug development and approvals, medical device development and approvals, post-market surveillance, market access and reimbursement/coverage decision making, and clinical & regulatory decision making. The drug development and approval segment dominated the RWE solutions market owing to increasing number of clinical trials specifically in the field of oncology and cardiovascular therapeutics. The drug development and approvals segment is further sub-segmented into oncology, cardiovascular disease, neurology, immunology, and other therapeutic areas. Cardiovascular disease segment is expected to witness fastest growth rate during the forecast period owing to increasing prevalence of CVDs and growing development of cardiovascular registries.

“Pharmaceutical and medical device companies are expected to witnessing fastest growth during the forecast period”

Based on end users, the RWE solutions market is segmented into pharmaceutical & medical device companies, healthcare providers, healthcare payers, and other end users. The pharmaceutical & medical device companies segment are expected to witness the fastest growth rate through 2027. Pharmaceutical companies require data describing both the approved and medically accepted alternative uses of previously approved drugs. Increasing growth in investments on pharmaceutical and medical device R&D and growing number of approvals are driving the use of RWE solutions in this segment.  Additionally, the use of RWE solutions in meeting regulatory compliances is increasing along with payer demands related to HEOR, which are also the key factors supporting the growth of RWE solutions market.

“North America leads the RWE solutions market by region”

North America accounted for the largest share of the global RWE solutions market. Majority of established players are based in North America. Furthermore, rising geriatric population is contributing to increase in chronic disease in the region, which is driving the demand for new drugs and medical devices, thereby catering to an increasing demand for evidence generation during clinical trials and post-market surveillance activities. The Asia Pacific market is projected to register the highest CAGR during the forecast period. Market growth in the Asia Pacific is attributed to the increasing government initiatives for the adoption of RWE studies.

The break-down of primary participants is as mentioned below:


  • By Company Type - Tier 1:40%, Tier 2: 35%, and Tier 3: 25%

  • By Designation - C-level: 35%, Director-level: 45%,and Others: 20%

  • By Region - North America: 55%,Europe: 20%,AsiaPacific: 15%,Latin America: 5%, and Middle East and Africa : 5%.


Key players in the RWE Solutions Market

The key players operating in the RWE solutions market include IQVIA Holdings Inc. (US), IBM Corporation (US), OPTUM Inc. (US), Icon Plc (Ireland), Syneos Health Inc. (US), Parexel International Corporation (US).

Research Coverage:

The report analyzes the RWE Solutions market and aims at estimating the market size and future growth potential of various market segments, based on component, applications, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, solution offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:


  • Market Penetration: Comprehensive information on the solution portfolios of the top players in the RWE solutions market. The report analyzes this market by component, application, end user, and region.

  • Market Development: Comprehensive information on the lucrative emerging markets, by component, application, end user, and region

  • Market Diversification: Exhaustive information about the solution portfolios, growing geographies, recent developments, and investments in the RWE solutions market

  • Competitive Assessment: In-depth assessment of market ranking, growth strategies, solution offerings, and capabilities of the leading players in the RWE solutions market

Real World Evidence Solutions Market by Component (Services, Disparate Data Sets, (Claims, Clinical, Pharmacy, Patient), Application (Oncology, Cardiovascular, Neurology, Immunology), End User (Pharma, Medtech, Payers, Providers) - Global Forecast to 2027

Table Of Contents

1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.2.1 Inclusions And Exclusions
1.2.2 Markets Covered
1.2.3 Years Considered For The Study
1.3 Currency
Table 1 Exchange Rates Utilized For Conversion To Usd
1.4 Limitations
1.5 Stakeholders
1.6 Summary Of Changes

2 Research Methodology
2.1 Research Data
Figure 1 Research Design
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
Figure 2 Primary Sources
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Insights From Primary Experts
Figure 3 Breakdown Of Primary Interviews: Supply-Side And Demand-Sideparticipants
Figure 4 Breakdown Of Primary Interviews (Supply-Side): By Companytype, Designation, And Region
2.2 Market Size Estimation: RWE Solutions Market
Figure 5 Supply-Side Market Size Estimation: Revenue Share Analysis
Figure 6 Market Size Estimation: Segmental Extrapolation
Figure 7 Cagr Projections From The Analysis Of Drivers, Restraints,Opportunities, And Challenges
Figure 8 Cagr Projections: Overall RWE Solutions Market
2.3 Market Breakdown And Data Triangulation
Figure 9 Data Triangulation Methodology
2.4 Market Ranking Analysis
2.5 Assumptions For The Study
2.6 Risk Assessment
Table 2 Risk Assessment:  Solutions Market
2.7 Limitations
2.7.1 Methodology-Related Limitations

3 Executive Summary
Figure 10 RWE Solutions Market, By Component, 2022 Vs. 2027 (Usd Million)
Figure 11 Data Sets Market, By Type, 2022 Vs. 2027 (Usd Million)
Figure 12 Disparate Data Sets Market, By Type, 2022 Vs. 2027 (Usd Million)
Figure 13 RWE Solutions Market, By Application, 2022 Vs. 2027 (Usd Million)
Figure 14 RWE Solutions In Drug Development And Approvals Market, By Type, 2022 Vs.2027 (Usd Million)
Figure 15 RWE Solutions Market, By End User, 2022 Vs. 2027 (Usd Million)
Figure 16 RWE Solutions Market: Geographic Snapshot

4 Premium Insights
4.1 RWE Solutions Market Overview
Figure 17 Support From Regulatory Bodies For The Use Of RWE Solutions Is Amajor Factor Driving The Market Growth
4.2 Asia Pacific: RWE Solutions Market, By End User And Country (2021)
Figure 18 Japan Accounted For The Largest Share Of The Asia Pacific Market In2021
4.3 RWE Solutions Market: Geographic Growth Opportunities
Figure 19 China To Register The Highest Growth Rate During The Forecast Period
4.4 Regional Mix: RWE Solutions Market (2022−2027)
Figure 20 North America Will Continue To Dominate The RWE Solutions Marketduring The Forecast Period
4.5 RWE Solutions Market: Developed Vs. Emerging Markets
Figure 21 Emerging Markets To Register Higher Growth Rates During Theforecast Period

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
Figure 22 RWE Solutions Market: Drivers, Restraints, Opportunities, Andchallenges
Table 3 Market Dynamics: Impact Analysis
5.2.1 Drivers
5.2.1.1 Rise In The Geriatric Population And The Subsequent Increase In The Prevalence Of Chronicdiseases
5.2.1.2 Shift From Volume- To Value-Based Care
5.2.1.3 Potential Of RWE In Reducing Drug Development Costs And Expediting The Drug Developmentprocess
5.2.1.4 Increased R&D Spending For The Development Of New Pharmaceutical Products And Medicaldevices
Figure 23 Number Of Clinical Trials Started During 2015–2020
5.2.1.5 Support From Regulatory Bodies For The Use Of RWE Solutions
5.2.2 Restraints
5.2.2.1 Reluctance Of Medical Practitioners And Researchers To Rely On Real-World Studies
5.2.3 Opportunities
5.2.3.1 Growth Opportunities In Emerging Markets
5.2.3.2 Rise In Focus On End-To-End RWE Services
5.2.4 Challenges
5.2.4.1 Lack Of Universally Accepted Methodology Standards And Data Processing Infrastructure
5.2.4.2 Shortage Of Skilled Professionals

6 Industry Insights
6.1 Industry Trends
6.1.1 Emerging Role Of Wearable Devices
Figure 24 Utilization Of Wearables In Clinical Trials, By Therapeutic Area,2019
6.1.2 Social Media-Sourced RWE
6.1.3 Rise In The Use Of Rwd And RWE Across The Pharmaceutical Industry
Figure 25 Recommended Investment Model For Rwd And RWE
6.1.4 Internal Vs. Outsourced RWE Analytics Approach
Figure 26 Internal Vs. Outsourced RWE Analytics Approach
6.1.5 Incorporation Of Artificial Intelligence In Rwd Management
6.2 Real-World Data Sources
Table 4 Indicative List Of National Databases In Developed Countries
6.3 Ecosystem Analysis
Figure 27 Ecosystem Coverage: Parent Market (Healthcare It Solutions)
Figure 28 Ecosystem Coverage: RWE Solutions Market
6.4 Porter’s Five Forces Analysis
Table 5 Porter’s Five Forces Analysis
6.4.1 Threat Of New Entrants
6.4.2 Bargaining Power Of Suppliers
6.4.3 Bargaining Power Of Buyers
6.4.4 Threat Of Substitutes
6.4.5 Intensity Of Competitive Rivalry
6.5 Pricing Analysis
6.5.1 Average Selling Price
6.5.2 Hcit Expenditure/Pricing Analysis
6.5.2.1 North America
Table 6 North America: Healthcare Expenditure, By Country
6.5.2.2 Europe
6.5.2.3 Asia Pacific
Table 7 Japan: Healthcare It Initiatives And Funding
6.6 Technology Analysis
6.7 Regulatory Bodies, Governments, And Other Organizations
6.7.1 North America
6.7.1.1 Case Examples
6.7.2 Europe
6.7.3 Asia Pacific
6.7.3.1 China
6.7.3.2 Japan
6.8 Patent Analysis
6.8.1 Patent Publication Trends For RWE Solutions
Figure 29 Global Patent Publication Trends In The RWE Solutions Market,2016–2021
6.8.2 Jurisdiction And Top Applicant Analysis
Figure 30 Top Applicants & Owners (Companies/Institutions) For Medicalsimulation Patents (January 2011 To June 2021)
6.8.3 Jurisdiction Analysis: Top Applicants (Countries) For Patents In The RWEsolutions Market
Figure 31 Jurisdiction Analysis: Top Applicant Countries For RWE Solutions,2016–2021
Table 8 List Of Patents In The RWE Solutions Market, 2019–2022
6.9 Key Conferences And Events (2022-2023)
Table 9 RWE Solutions Market: Detailed List Of Conferences And Events
6.10 Key Stakeholders And Buying Criteria
6.10.1 Key Stakeholders In Buying Process
Figure 32 Influence Of Stakeholders On Buying Process For Top 3applications
Table 10 Influence Of Stakeholders On Buying Process For Top 3applications
6.10.2 Buying Criteria
Figure 33 Key Buying Criteria For Top 3 Applications
Table 11 Key Buying Criteria For Top 3 End Users

7 RWE Solutions Market, By Component
7.1 Introduction
Table 12 RWE Solutions Market, By Component, 2020–2027 (Usd Million)
7.2 Services
7.2.1 Rising Need To Convert Data Into Actionable Evidence To Drive Demand
Table 13 RWE Services Offered By Key Market Players
Table 14 RWE Services Market, By Country, 2020–2027 (Usd Million)
7.3 Data Sets
Table 15 Data Sets Market, By Type, 2020–2027 (Usd Million)
Table 16 Data Sets Market, By Country, 2020–2027 (Usd Million)
7.3.1 Disparate Data Sets
Table 17 Disparate Data Sets Market, By Type, 2020–2027 (Usd Million)
Table 18 Disparate Data Sets Market, By Country, 2020–2027 (Usd Million)
7.3.1.1 Clinical Settings Data Set
7.3.1.1.1 Increasing Utilization Of Ehr Data For Trial Recruitment To Fuel Growth
Figure 34 Adoption Of Ehr By Hospital Service Type, 2019-2021
Table 19 Clinical Settings Data Sets Offered By Key Marketplayers
Table 20 Clinical Settings Disparate Data Sets Market, Bycountry, 2020–2027 (Usd Million)
7.3.1.2 Claims Data Set
7.3.1.2.1 Growing Need To Understand The Economic Benefits Of Drug Reimbursement Bypayers To Drive Growth
Table 21 Claims Data Sets Offered By Key Market Players
Table 22 Claims Disparate Data Sets Market, By Country, 2020–2027(Usd Million)
7.3.1.3 Pharmacy Data Set
7.3.1.3.1 Increasing Adoption Of E-Prescribing Systems To Drive Growth
Figure 35 Total E-Prescriptions And Controlled Substanceprescriptions In The Us (2018-2021)
Table 23 Pharmacy Data Sets Offered By Key Market Players
Table 24 Pharmacy Disparate Data Set Market, By Country, 2020–2027 (Usd Million)
7.3.1.4 Patient-Powered Data Set
7.3.1.4.1 Increasing Need To Access Opinions On Diseases And Treatments Across Socialmedia To Drive Growth
Table 25 Patient-Powered Data Sets Offered By Key Marketplayers
Table 26 RWE Patient-Powered Disparate Data Market, By Country,2020–2027 (Usd Million)
7.3.1.5 Registry-Based Data Sets
7.3.1.5.1 Increasing Number Of Disease Registries Is Driving The Demand For Registry-Baseddata Sets In Evidence Generation
Table 27 Use Of Registries For Evidence Generation
Table 28 Registry-Based Data Sets Offered By Key Marketplayers
Table 29 Registry-Based Disparate Data Sets Market, By Country,2020–2027 (Usd Million)
7.3.2 Integrated Data Sets
7.3.2.1 Increasing Demand For Integrated Data From Multiple Sources To Drive Growth
Table 30 Integrated Data Sets Offered By Key Market Players
Table 31 Integrated Data Sets Market, By Country, 2020–2027 (Usdmillion)

8 RWE Solutions Market, By Application
8.1 Introduction
Figure 36 Number Of Clinical Trials (Completed), By Condition/Disease,
Table 32 RWE Solutions Market, By Application, 2020–2027 (Usd Million)
8.2 Drug Development And Approvals
Table 33 RWE Solutions Market In Drug Development And Approvals, By Type 2020–2027 (Usd Million)
8.2.1 Oncology
8.2.1.1 Growing Number Of Clinical Trials Focused On Cancer Treatment To Drive Growth
Table 34 List Of Pipeline Drugs For Oncology (2018)
Table 35 Drug Development And Approvals Market In Oncology, Bycountry, 2020–2027 (Usd Million)
8.2.2 Cardiovascular Disease
8.2.2.1 High Prevalence Of Cvd To Drive Growth
Table 36 List Of Pipeline Drugs For Cardiovascular Disease (Byfebruary 2022)
Table 37 Drug Development And Approvals Market In Cardiovasculardisease, By Country, 2020–2027 (Usd Million)
8.2.3 Neurology
8.2.3.1 Growing Prevalence Of Neurological Disorders To Drive Growth
Table 38 Drug Development And Approvals Market In Neurology, Bycountry, 2020–2027 (Usd Million)
8.2.4 Immunology
8.2.4.1 Increasing Focus On Developing Innovative Products To Drive Growth
Table 39 Drug Development And Approvals Market In Immunology, By Country, 2020–2027 (Usd Million)
8.2.5 Other Therapeutic Areas
Table 40 Drug Development And Approvals Market In Other Therapeuticareas, By Country, 2020–2027 (Usd Million)
8.3 Medical Device Development And Approvals
8.3.1 Increasing Research In Medical Device Development To Drive Demand
Table 41 RWE Solutions Market In Medical Device Development And Approvals,By Country, 2020–2027 (Usd Million)
8.4 Post-Market Surveillance
8.4.1 Emr And Product/Patient Registries Have Become Key Data Sources Forgenerating Evidence In Post-Market Surveillance
Table 42 RWE Solutions Market In Post-Market Surveillance, By Country,2020–2027 (Usd Million)
8.5 Market Access And Reimbursement/Coverage Decision Making
8.5.1 Growing Use Of RWE Solutions To Develop Economic And Budget Impactmodels
Table 43 RWE Solutions Market In Market Access Andreimbursement/Coverage Decision Making, By Country, 2020–2027 (Usd Million)
8.6 Clinical And Regulatory Decision Making
8.6.1 Limited Validity Of Randomized Controlled Trials Driving The Use Of RWEsolutions In The Segment
Table 44 RWE Solutions Market In Clinical And Regulatory Decision Making, Bycountry, 2020–2027 (Usd Million)

9 RWE Solutions Market, By End User
9.1 Introduction
Table 45 RWE Solutions Market, By End User, 2020–2027 (Usd Million)
9.2 Pharmaceutical & Medical Device Companies
9.2.1 Increased R&D Expenditure In Innovative Medicines To Drive Market Growth
Figure 37 Fda Phase Transition Success Rates, 2011–2020
Figure 38 Annual Drug Approvals By Cder (Fda), 2011–2021
Figure 39 R&D Spending Of Pharma Member Companies, 2011–2020
Table 46 RWE Solutions Market For Pharmaceutical & Medical Devicecompanies, By Country, 2020–2027 (Usd Million)
9.3 Healthcare Payers
9.3.1 Increased Focus On Outcome-Based Payment Models To Drive Demand
Table 47 RWE Solutions Market For Healthcare Payers, By Country, 2020–2027(Usd Million)
9.4 Healthcare Providers
9.4.1 Rise In The Need To Improve The Profitability Of Healthcare Providers Toboost Use
Table 48 RWE Solutions Market For Healthcare Providers, By Country, 2020–2027 (Usd Million)
9.5 Other End Users
Table 49 RWE Solutions Market For Other End Users, By Country, 2020–2027 (Usdmillion)

10 RWE Solutions Market, By Region
10.1 Introduction
Table 50 RWE Solutions Market, By Region, 2020–2027 (Usd Million)
10.2 North America
Figure 40 North America: RWE Solutions Market Snapshot
Table 51 North America: RWE Solutions Market, By Country, 2020–2027 (Usd Million)
Table 52 North America: RWE Solutions Market, By Component, 2020–2027 (Usdmillion)
Table 53 North America: RWE Solutions Data Sets Market, By Type, 2020–2027 (Usdmillion)
Table 54 North America: Disparate Data Sets Market, By Type, 2020–2027 (Usdmillion)
Table 55 North America: RWE Solutions Market, By Application, 2020–2027 (Usdmillion)
Table 56 North America: RWE Solutions In Drug Development And Approvalsmarket, By Type, 2020–2027 (Usd Million)
Table 57 North America: RWE Solutions Market, By End User, 2020–2027 (Usdmillion)
10.2.1 Us
10.2.1.1 The Us Accounted For The Largest Share Of The North American Market
Table 58 Us: Macroeconomic Indicators
Table 59 Us: RWE Solutions Market, By Component, 2020–2027 (Usdmillion)
Table 60 Us: RWE Solutions Data Sets Market, By Type, 2020–2027 (Usdmillion)
Table 61 Us: Disparate Data Sets Market, By Type, 2020–2027 (Usdmillion)
Table 62 Us: RWE Solutions Market, By Application, 2020–2027 (Usdmillion)
Table 63 Us: RWE Solutions In Drug Development And Approvalsmarket, By Type, 2020–2027 (Usd Million)
Table 64 Us: RWE Solutions Market, By End User, 2020–2027 (Usdmillion)
10.2.2 Canada
10.2.2.1 Growing Number Of Clinical Trials In Canada To Drive Market Growth
Table 65 Canada: Macroeconomic Indicators
Table 66 Canada: RWE Solutions Market, By Component, 2020–2027 (Usdmillion)
Table 67 Canada: RWE Solutions Data Sets Market, By Type, 2020–2027(Usd Million)
Table 68 Canada: Disparate Data Sets Market, By Type, 2020–2027 (Usdmillion)
Table 69 Canada: RWE Solutions Market, By Application, 2020–2027 (Usdmillion)
Table 70 Canada: RWE Solutions In Drug Development And Approvalsmarket, By Type, 2020–2027 (Usd Million)
Table 71 Canada: RWE Solutions Market, By End User, 2020–2027 (Usdmillion)
10.3 Europe
Table 72 Europe: RWE Solutions Market, By Country, 2020–2027 (Usd Million)
Table 73 Europe: RWE Solutions Market, By Component, 2020–2027 (Usd Million)
Table 74 Europe: RWE Solutions Data Sets Market, By Type, 2020–2027 (Usd Million)
Table 75 Europe: Disparate Data Sets Market, By Type, 2020–2027 (Usd Million)
Table 76 Europe: RWE Solutions Market, By Application, 2020–2027 (Usd Million)
Table 77 Europe: RWE Solutions In Drug Development And Approvals Market, Bytype, 2020–2027 (Usd Million)
Table 78 Europe: RWE Solutions Market, By End User, 2020–2027 (Usd Million)
10.3.1 Germany
10.3.1.1 High Pharmaceutical R&D Spending In Germany To Boost The Market Growth
Table 79 Germany: Macroeconomic Indicators
Table 80 Germany: RWE Solutions Market, By Component, 2020–2027(Usd Million)
Table 81 Germany: RWE Solutions Data Sets Market, By Type, 2020–2027(Usd Million)
Table 82 Germany: Disparate Data Sets Market, By Type, 2020–2027 (Usdmillion)
Table 83 Germany: RWE Solutions Market, By Application, 2020–2027(Usd Million)
Table 84 Germany: RWE Solutions In Drug Development Andapprovals Market, By Type, 2020–2027 (Usd Million)
Table 85 Germany: RWE Solutions Market, By End User, 2020–2027 (Usdmillion)
10.3.2 Uk
10.3.2.1 The Growing Adoption Of Hta In The Uk Supports Market Growth
Table 86 Uk: Macroeconomic Indicators
Table 87 Uk: RWE Solutions Market, By Component, 2020–2027 (Usdmillion)
Table 88 Uk: RWE Solutions Data Sets Market, By Type, 2020–2027 (Usdmillion)
Table 89 Uk: Disparate Data Sets Market, By Type, 2020–2027 (Usdmillion)
Table 90 Uk: RWE Solutions Market, By Application, 2020–2027 (Usdmillion)
Table 91 Uk: RWE Solutions In Drug Development And Approvalsmarket, By Type, 2020–2027 (Usd Million)
Table 92 Uk: RWE Solutions Market, By End User, 2020–2027 (Usdmillion)
10.3.3 France
10.3.3.1 High Number Of Oncology Clinical Trials In France To Drive Market Growth
Table 93 France: Macroeconomic Indicators
Table 94 France: RWE Solutions Market, By Component, 2020–2027 (Usdmillion)
Table 95 France: RWE Solutions Data Sets Market, By Type, 2020–2027(Usd Million)
Table 96 France: Disparate Data Sets Market, By Type, 2020–2027 (Usdmillion)
Table 97 France: RWE Solutions Market, By Application, 2020–2027 (Usdmillion)
Table 98 France: RWE Solutions In Drug Development And Approvalsmarket, By Type, 2020–2027 (Usd Million)
Table 99 France: RWE Solutions Market, By End User, 2020–2027 (Usdmillion)
10.3.4 Italy
10.3.4.1 The Demand For RWE In Italy Is High Due To The Widespread Use Of Pay-For-Outcomes
Table 100 Italy: Macroeconomic Indicators
Table 101 Italy: RWE Solutions Market, By Component, 2020–2027 (Usdmillion)
Table 102 Italy: RWE Solutions Data Sets Market, By Type, 2020–2027(Usd Million)
Table 103 Italy: Disparate Data Sets Market, By Type, 2020–2027 (Usdmillion)
Table 104 Italy: RWE Solutions Market, By Application, 2020–2027 (Usdmillion)
Table 105 Italy: RWE Solutions In Drug Development And Approvalsmarket, By Type, 2020–2027 (Usd Million)
Table 106 Italy: RWE Solutions Market, By End User, 2020–2027 (Usdmillion)
10.3.5 Spain
10.3.5.1 Rising R&D Expenditure To Propel Market Growth In Spain
Table 107 Spain: Macroeconomic Indicators
Table 108 Spain: RWE Solutions Market, By Component, 2020–2027 (Usdmillion)
Table 109 Spain: RWE Solutions Data Sets Market, By Type, 2020–2027(Usd Million)
Table 110 Spain: Disparate Data Sets Market, By Type, 2020–2027 (Usdmillion)
Table 111 Spain: RWE Solutions Market, By Application, 2020–2027 (Usdmillion)
Table 112 Spain: RWE Solutions In Drug Development And Approvalsmarket, By Type, 2020–2027 (Usd Million)
Table 113 Spain: RWE Solutions Market, By End User, 2020–2027 (Usdmillion)
10.3.6 Rest Of Europe
Table 114 Rest Of Europe: RWE Solutions Market, By Component, 2020–2027(Usd Million)
Table 115 Rest Of Europe: RWE Solutions Data Sets Market, By Type, 2020–2027 (Usd Million)
Table 116 Rest Of Europe: Disparate Data Sets Market, By Type, 2020–2027 (Usdmillion)
Table 117 Rest Of Europe: RWE Solutions Market, By Application, 2020–2027(Usd Million)
Table 118 Rest Of Europe: RWE Solutions In Drug Development Andapprovals Market, By Type, 2020–2027 (Usd Million)
Table 119 Rest Of Europe: RWE Solutions Market, By End User, 2020–2027 (Usdmillion)
10.4 Asia Pacific
Figure 41 Asia Pacific: RWE Solutions Market Snapshot
Table 120 Asia Pacific: RWE Solutions Market, By Country, 2020–2027 (Usd Million)
Table 121 Asia Pacific: RWE Solutions Market, By Component, 2020–2027 (Usdmillion)
Table 122 Asia Pacific: RWE Solutions Data Sets Market, By Type, 2020–2027 (Usdmillion)
Table 123 Asia Pacific: Disparate Data Sets Market, By Type, 2020–2027 (Usd Million)
Table 124 Asia Pacific: RWE Solutions Market, By Application, 2020–2027 (Usdmillion)
Table 125 Asia Pacific: RWE Solutions In Drug Development And Approvals Market,By Type, 2020–2027 (Usd Million)
Table 126 Asia Pacific: RWE Solutions Market, By End User, 2020–2027 (Usd Million)
10.4.1 Japan
10.4.1.1 Stringent Regulatory Scenario In Japan To Restrain Market Growth
Table 127 Japan: Macroeconomic Indicators
Table 128 Japan: RWE Solutions Market, By Component, 2020–2027 (Usdmillion)
Table 129 Japan: RWE Solutions Data Sets Market, By Type, 2020–2027(Usd Million)
Table 130 Japan: Disparate Data Sets Market, By Type, 2020–2027 (Usd Million)
Table 131 Japan: RWE Solutions Market, By Application, 2020–2027 (Usdmillion)
Table 132 Japan: RWE Solutions In Drug Development And Approvalsmarket, By Type, 2020–2027 (Usd Million)
Table 133 Japan: RWE Solutions Market, By End User, 2020–2027 (Usdmillion)
10.4.2 China
10.4.2.1 Low Cost Of Clinical Trials And Large Pharmaceutical R&D Base In China To Drive Marketgrowth
Table 134 China: Macroeconomic Indicators
Table 135 China: RWE Solutions Market, By Component, 2020–2027 (Usdmillion)
Table 136 China: RWE Solutions Data Sets Market, By Type, 2020–2027(Usd Million)
Table 137 China: Disparate Data Sets Market, By Type, 2020–2027 (Usdmillion)
Table 138 China: RWE Solutions Market, By Application, 2020–2027 (Usdmillion)
Table 139 China: RWE Solutions In Drug Development And Approvalsmarket, By Type, 2020–2027 (Usd Million)
Table 140 China: RWE Solutions Market, By End User, 2020–2027 (Usdmillion)
10.4.3 India
10.4.3.1 Growing Adoption Of Outcomes-Based Research Among Pharmaceutical And Medicaldevice Manufacturers In India To Drive Market Growth
Table 141 India: Macroeconomic Indicators
Table 142 India: RWE Solutions Market, By Component, 2020–2027 (Usdmillion)
Table 143 India: RWE Solutions Data Sets Market, By Type, 2020–2027(Usd Million)
Table 144 India: Disparate Data Sets Market, By Type, 2020–2027 (Usdmillion)
Table 145 India: RWE Solutions Market, By Application, 2020–2027 (Usdmillion)
Table 146 India: RWE Solutions In Drug Development And Approvalsmarket, By Type, 2020–2027 (Usd Million)
Table 147 India: RWE Solutions Market, By End User, 2020–2027 (Usdmillion)
10.4.4 Rest Of Asia Pacific
Table 148 Rest Of Asia Pacific: RWE Solutions Market, By Component, 2020–2027 (Usd Million)
Table 149 Rest Of Asia Pacific: RWE Solutions Data Sets Market, By Type,2020–2027 (Usd Million)
Table 150 Rest Of Asia Pacific: Disparate Data Sets Market, By Type, 2020–2027(Usd Million)
Table 151 Rest Of Asia Pacific: RWE Solutions Market, By Application, 2020–2027 (Usd Million)
Table 152 Rest Of Asia Pacific: RWE Solutions In Drug Development Andapprovals Market, By Type, 2020–2027 (Usd Million)
Table 153 Rest Of Asia Pacific: RWE Solutions Market, By End User, 2020–2027(Usd Million)
10.5 Latin America
10.5.1 Increased Healthcare Expenditure To Support Market Growth
Table 154 Latin America: RWE Solutions Market, By Component, 2020–2027 (Usdmillion)
Table 155 Latin America: RWE Solutions Data Sets Market, By Type, 2020–2027(Usd Million)
Table 156 Latin America: Disparate Data Sets Market, By Type, 2020–2027 (Usdmillion)
Table 157 Latin America: RWE Solutions Market, By Application, 2020–2027 (Usdmillion)
Table 158 Latin America: RWE Solutions In Drug Development And Approvalsmarket, By Type, 2020–2027 (Usd Million)
Table 159 Latin America: RWE Solutions Market, By End User, 2020–2027 (Usdmillion)
10.6 Middle East & Africa
10.6.1 Growing Availability Of Healthcare Funding In The Middle East Offersopportunities For Market Growth
Table 160 Middles East & Africa: RWE Solutions Market, By Component, 2020–2027 (Usd Million)
Table 161 Middles East & Africa: RWE Solutions Data Sets Market, By Type,2020–2027 (Usd Million)
Table 162 Middles East & Africa: Disparate Data Sets Market, By Type, 2020–2027 (Usd Million)
Table 163 Middles East & Africa: RWE Solutions Market, By Application, 2020–2027 (Usd Million)
Table 164 Middles East & Africa: RWE Solutions In Drug Development Andapprovals Market, By Type, 2020–2027 (Usd Million)
Table 165 Middles East & Africa: RWE Solutions Market, By End User, 2020–2027 (Usd Million)

11 Competitive Landscape
11.1 Overview
11.2 Strategies Adopted By Key Players /Right To Win
Table 166 Overview Of Strategies Adopted By Players In The RWE Solutionsmarket
11.3 Revenue Share Analysis Of Key Players
Figure 42 Revenue Analysis Of Key Players In The RWE Solutions Market
11.4 Market Ranking Analysis
Figure 43 RWE Solutions Market Ranking, By Key Player, 2021
11.5 Competitive Benchmarking
Table 167 RWE Solutions Market: Detailed List Of Small & Medium Players
11.6 Company Footprint
11.6.1 End-User Footprint Of Companies
11.6.2 Product Footprint Of Companies
11.6.3 Regional Footprint Of Companies
11.7 Company Evaluation Quadrant
11.7.1 Stars
11.7.2 Emerging Leaders
11.7.3 Pervasive Players
11.7.4 Participants
Figure 44 RWE Solutions Market: Company Evaluation Quadrant (2021)
11.8 Company Evaluation Quadrant For Start-Ups/Smes
11.8.1 Progressive Companies
11.8.2 Starting Blocks
11.8.3 Responsive Companies
11.8.4 Dynamic Companies
Figure 45 Start-Up/Sme Evaluation Quadrant (2021)
11.9 Competitive Scenario
11.9.1 Fda Approvals/Service Enhancements
Table 168 Fda Approvals/Enhancements, 2019–2022
11.9.2 Deals
Table 169 Deals, 2019–2022
11.9.3 Other Developments
Table 170 Other Developments, 2019–2022

12 Company Profiles
12.1 Key Players
(Business Overview, Products, Recent Developments, Mnm View)*
12.1.1 Iqvia Holdings Inc.
Table 171 Iqvia Holdings Inc.: Business Overview
Figure 46 Iqvia Holdings Inc: Company Snapshot (2021)
12.1.2 Ibm Corporation (Ibm)
Table 172 Ibm Corporation: Business Overview
Figure 47 Ibm Corporation: Company Snapshot (2021)
12.1.3 Optum Inc. (A Subsidiary Of The United Health Group, Inc.)
Table 173 Optum Inc.: Business Overview
Figure 48 Optum Inc.: Company Snapshot (2021)
12.1.4 Icon Plc.
Table 174 Icon Plc.: Business Overview
Figure 49 Icon Plc.: Company Snapshot (2021)
12.1.5 Syneos Health, Inc.
Table 175 Syneos Health Inc.: Business Overview
Figure 50 Syneos Health Inc.: Company Snapshot (2021)
12.1.6 Parexel International Corporation
Table 176 Parexel International Corporation: Business Overview
12.1.7 Thermo Fisher Scientific Inc.
Table 177 Thermo Fisher Scientific Inc.: Business Overview
Figure 51 Thermo Fisher Scientific, Inc.: Company Snapshot (2021)
12.1.8 Labcorp Holdings
Table 178 Labcorp Holdings: Business Overview
Figure 52 Labcorp Holdings: Company Snapshot (2021)
12.1.9 Oracle Corporation
Table 179 Oracle Corporation: Business Overview
Figure 53 Oracle Corporation: Company Snapshot (2021)
12.1.10 Elevance Health
Table 180 Elevance Health: Business Overview
Figure 54 Elevance Health: Company Snapshot (2021)
12.1.11 Sas Institute
Table 181 Sas Institute: Business Overview
Figure 55 Sas Institute: Company Snapshot (2021)
12.1.12 Aetion Inc.
Table 182 Aetion Inc.: Business Overview
12.1.13 Trinetx Llc
Table 183 Trinetx Llc: Business Overview
12.1.14 Trinity Life Sciences
Table 184 Trinity Life Sciences: Business Overview
12.1.15 Perkinelmer Inc.
Table 185 Perkinelmer Inc.: Business Overview
Figure 56 Perkinelmer Inc.: Company Snapshot (2021)
12.1.16 Cognizant Technology Solutions Corporation
Table 186 Cognizant Technology Solutions Corporation: Businessoverview
Figure 57 Cognizant Technology Solutions Corporation: Companysnapshot (2021)
12.1.17 Clinigen
Table 187 Clinigen: Business Overview
Figure 58 Clinigen: Company Snapshot (2021)
12.1.18 Cegedim Health Data
Table 188 Cegedim Health Data: Business Overview
Figure 59 Cegedim Health Data: Company Snapshot (2021)
12.1.19 Verantos Inc.
Table 189 Verantos Inc.: Business Overview
12.1.20 Medpace Holdings Inc.
Table 190 Medpace Holdings Inc.: Business Overview
Figure 60 Medpce Holdings Inc.: Company Snapshot (2021)
*Details On Business Overview, Products, Recent Developments, Mnm View Might Not Be Captured In Case Ofunlisted Companies.
12.2 Other Players
12.2.1 Healthverity Inc.
12.2.2 Datavant
12.2.3 Syapse Inc.
12.2.4 Tempus Labs Inc.
12.2.5 Flatiron Health

13 Appendix
13.1 Discussion Guide
13.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.3 Customization Options
13.4 Related Reports
13.5 Author Details

  • Global Surgical Overalls Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Surgical Overalls market was valued at US$ 679.9 million in 2023 and is anticipated to reach US$ 870.5 million by 2030, witnessing a CAGR of 3.1% during The forecast period 2024-2030. According to our research, The global market for medical devices is estimated at US$ 603 billion in The year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of The global GDP and is continuously rising in recent years ......
  • Global Medical or Healthcare Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 110
    According to our LPI (LP Information) latest study, the global Medical or Healthcare market size was valued at US$ million in 2023. With growing demand in downstream market, the Medical or Healthcare is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Medical or Healthcare market. Medical or Healthcare are expected to show stable growth in the future market. However, product differ......
  • Global Hospital Gas Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 100
    According to our LPI (LP Information) latest study, the global Hospital Gas market size was valued at US$ million in 2023. With growing demand in downstream market, the Hospital Gas is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Hospital Gas market. Hospital Gas are expected to show stable growth in the future market. However, product differentiation, reducing costs, and suppl......
  • Global Nurse Call Systems Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 135
    According to our LPI (LP Information) latest study, the global Nurse Call Systems market size was valued at US$ 1633.1 million in 2023. With growing demand in downstream market, the Nurse Call Systems is forecast to a readjusted size of US$ 3280.4 million by 2030 with a CAGR of 10.5% during review period. The research report highlights the growth potential of the global Nurse Call Systems market. Nurse Call Systems are expected to show stable growth in the future market. However, product......
  • Global Pediatric Healthcare Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 118
    According to our LPI (LP Information) latest study, the global Pediatric Healthcare market size was valued at US$ 136230 million in 2023. With growing demand in downstream market, the Pediatric Healthcare is forecast to a readjusted size of US$ 177330 million by 2030 with a CAGR of 3.8% during review period. The research report highlights the growth potential of the global Pediatric Healthcare market. Pediatric Healthcare are expected to show stable growth in the future market. However, ......
  • Global Telepharmacy Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 100
    Market Overview of Global Telepharmacy market: According to our latest research, the global Telepharmacy market looks promising in the next 5 years. As of 2022, the global Telepharmacy market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Telepharmacy market, with a systema......
  • Global Vinca Alkaloid Compounds Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 115
    Market Overview of Global Vinca Alkaloid Compounds market: According to our latest research, the global Vinca Alkaloid Compounds market looks promising in the next 5 years. As of 2022, the global Vinca Alkaloid Compounds market was estimated at USD 26.93 million, and it's anticipated to reach USD 44.76 million in 2028, with a CAGR of 8.84% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of th......
  • Global Bladder Cancer Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 116
    Market Overview of Global Bladder Cancer market: According to our latest research, the global Bladder Cancer market looks promising in the next 5 years. As of 2022, the global Bladder Cancer market was estimated at USD 3886.47 million, and it's anticipated to reach USD 13709.57 million in 2028, with a CAGR of 23.38% during the forecast years. Bladder cancer is a disease in which cells in the urinary bladder start growing abnormally and uncontrollably. The main types of bladde......
  • Global Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheters Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 115
    Market Overview of Global Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheters market: According to our latest research, the global Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheters market looks promising in the next 5 years. As of 2022, the global Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheters market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs